NL7908853A - Gesubstitueerde 2 fenylamino-imidazolinen. - Google Patents
Gesubstitueerde 2 fenylamino-imidazolinen. Download PDFInfo
- Publication number
- NL7908853A NL7908853A NL7908853A NL7908853A NL7908853A NL 7908853 A NL7908853 A NL 7908853A NL 7908853 A NL7908853 A NL 7908853A NL 7908853 A NL7908853 A NL 7908853A NL 7908853 A NL7908853 A NL 7908853A
- Authority
- NL
- Netherlands
- Prior art keywords
- imidazoline
- formula
- pharmaceutically suitable
- suitable salts
- amino
- Prior art date
Links
- -1 PHENYLAMINO IMIDAZOLINES Chemical class 0.000 title claims description 18
- 150000003839 salts Chemical class 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 230000001882 diuretic effect Effects 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 208000006218 bradycardia Diseases 0.000 claims description 4
- 230000036471 bradycardia Effects 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 239000003495 polar organic solvent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 9
- 229960002896 clonidine Drugs 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- AWSIIMOTYXRBBD-UHFFFAOYSA-N 2-phenyl-4,5-dihydroimidazol-1-amine Chemical class NN1CCN=C1C1=CC=CC=C1 AWSIIMOTYXRBBD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- QRECIVPUECYDDM-UHFFFAOYSA-N 2-chlorooxane Chemical compound ClC1CCCCO1 QRECIVPUECYDDM-UHFFFAOYSA-N 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- JCOPITWIWLFFPC-UHFFFAOYSA-N n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1NC1=CC=CC=C1 JCOPITWIWLFFPC-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
W...... ' - ' > — - —"" * V.
-' . * VO 8793
Gesubstitueerde 2 fenylandno-imidazolinen.
De uitvinding betreft een reeks gesubstitueerde 2-fenyl-amino-imidazolinen-(2) met de formule 1 van bet formuleblad, en bun farmaceutisch geschikte zouten. In deze formule 1 stelt R een groep met de formule 5 voor, waarin nr3 of b; en Rg waterstof, fluor, chloor of brocm danwel een alkylgroep met 5 1-h koolstof atomen voorstellen.
De uitvinding betreft tevens geneesmiddelen met bloëddruk-verlagende, bradycardie en diuretische activiteiten die als actieve stoffen een of meer verbindingen met de formule 1 bevatten. Tevens betreft de uitvinding werkwijzen voor het be-10 reiden van de verbindingen met de formule 1.
De verbindingen met de formule 1 kunnen warden verkregen door een 2-fenylimino-imidazolidine met-de formule 2 of een . natriumzout daarvan met een verbinding met de formule 3 of It em te zetten, waarin n de bovenweergegeven betekenis bezit en 15 X een halogeenatoam (chloor of broom), een alkoxy groep of acyloxygrcep voor stelt. De verbindingen 3 en kunnen worden gebruikt in de zuivere vorm of in situ worden verkregen volgens op zichzelf bekende methoden (Rec.Trav.Chim. Pays-Bas 98¾ 371-80 (1979)).
20 Ihdien X een halogeenatoom is wordt de reactie liefst uitgevoerd in polaire of niet polaire oplosmiddelen en wel bij een temperatuur tussen -50°C en kamertemperatuur. Indien'X een alkoxy- of acyloxygroep is, of indien de verbindingen met de formule U worden gebruikt, wordt de reactie liefst uitgevoerd 25 in dimethylfoimamide of acetonitrile en wel bij het kookpunt van deze oplosmiddelen.
De zouten kunnen worden verkregen uit de verbindingen met de formule 1 met farmaceutisch geschikte anorganische zuren, zoals zoutzuur, waterstofbremide, salpeterzuur, zwavelzuur of 30 fosforzuur, danwel met organische zuren, zoals.azijnzuur, 7908855 \ -2- t ; 4 · y> pr.cpionzuur, glycolzuur, malonzuur, barnsteenzuur, maleInezuur, hydroxymaleinezuur, fumaarzuur, appelzuur, "wijnsteenzuur, citroenzuur, glucuronzuur, benzoëzuur, amandelzuur, salleyIzuur, k-aminosalicylzuur, 2-fenoxybenzoëzuur, embonzuur, nicotinezuur of 5 is oni cotine zuur, of onder toepassing van sulfonzuren als methaan-sulfonzuur, ethaansulfonzuur, 2-bydroxyethaansulfonzuur, ethaan- 1,2-disulfonzuur, p-tolueensulfonzuur of naftaleen.-2-sulfonzuur.
De verbindingen met de formule 1 en hun zuuradditiezouten zijn bij 3T°C zowel^Saagzuur als .darmsap stabiel.
10 De nieuwe verbindingen bezitten evenals hun zuuradditie zouten een goede bloeddrukverlagende, bradycardie en diuretische acitiviieit. De oraal aan mensen toe te dienen dosès bedragen 0,3 tot 100 mg.
De onderhavige verbindingen hebben een aantal voordelen 15 vergeleken met hun voorlopers (verbindingen met de formule 1, waarin R = ïï); speciaal 2-,/Ëf-2,β-dichloorfenyl-ïï-(2-tetrahydropiranyl) aminq7-imidazoline-(2) en 2-^11-(2,6-dichloorfenyl)-H—(2-tetra-' hydrofuranyl) aminq/-imi dazoline-(2) vertonen diverse voordelen vergeleken met 2-(2, 6-di chlooranilino)- Δ2 -imidazoline (Clonidine).
20 'Zelfs bij hogere doses dan aangegeven in de volgende tabellen veranderen zij het gedrag van het proefdier niet; bovendien missen zij zowel stimulerende als remmende eigenschappen op de c^-adrenergische receptoren en het parasympathische systeem.
De verbinding n.l geeft op het proefdier een sterker en 25 langduriger bio'eddrükverlagend. effect dan clonidine zelf (tabel A) • en vertoont een gunstiger gedrag bij de proeven omtrent mogelijke neveneffecten.
Tabel A "bont aan, dat clonidine bij orale toediening aan een rat de aanvankelijke druk verhoogt en een perifeer ^-adrener-30 gisch effect heeft, welke eigenschap in de. clinische literatuur als ongewenst-wordt beschouwd (ïïunyor S.ÏT. et al. Brit.Med., U_, 23 (1975) Wing L.M.H. et al. Brit.Med., 136 (1977))i daarentegen ontbreekt deze bloeddrukverhogende fase na een equivalente dosis van verbinding n.l.' 35 Bovendien veroorzaakt de toediening van 5 /uM/kg clonidine 7908853 -3- λ * fk bij wakende honden na een aanvankelijke verlaging van de arteriële druk die 90 minuten duurt, een duidelijke verhoging van de arterx-ele druk, gepaard gaande met onrust- en tremor-symptaaen, die kunnen worden vergeleken met een rebound-bloeddrukverhoging waar- 5 genarren "bij mensen (Lesley Matier ¥. and Comer W.T., Annual Reports in Medicinal. Chemistry, 13 (1978) hoofdstuk 8 - Antihypertensive agents, hls.. Tl en 72); dezelfde dosis aan verbinding 1 levert daarentegen bij de hand slechts een durend, bloeddrukverlagend effect.
10 Tenslotte is verbinding n.l ko resp. 800 maal minder actief dan clcnidine bij het verminderen van de spontane bewegelijkheid bij rat en muis (tabel D), zodat de sedatieve activiteit nagenoeg kan. worden verwaarloosd; dit neveneffect is bij mensen .ongewenst (Lesley Matier W. en ·Comer W.T., 1978).
15 De onderhavige verbindingen kunnen oraal via een injectie of rectaal onder toepassing van .passende farmaceutische preparaten worden toegediend en wel in vaste,vloeibare of gesuspendeerde . ' vorm. (tabletten, capsules, flesjes, stropen, suppositoria enz.).
De volgende niet beperkende tabellen geven de farmacologische 20 eigenschappen van de'verbinding n.l, t.w. 2-^1-(2,6-dichloorfenyl)- II-(2-tetrahydropyranyl)amino/imidazoline-(2) en verbinding n.2, t.w. 2-/β-(2,5-dichloorfenyl)-H-(tetrahydrofuranyl)amino/imidazoline-^) weer.
Methode van onderzoek 25 De blceddrukverlagende en bradycardie-activiteiten zijn onderzocht bij wakende ratten en honden door een chronische incannulatie respectievelijk bij de carotis en de safena slagader alsmede een continue registratie via daarvoor passende toestellen.
30 De diuretische activiteit is onderzocht bij de wakende rat onder toepassing van een'vochtbelasting (fysiologische
O
zoutoplossing 25 cm3/kg, oraal).
35 « 7908853 » -4-
Tabel A:
Verbindingen. dosis Arteriele drukvariatie /uM/kg, _ ' __— ora&l' ~ 1 f amnr (z)' f dnur (*) mm Hg mm Hg mm Hg mm Hg _____ _ _ _ __
Ho. 1 1 -111· 190 -16 305 5 -19 > 320 ÜT 325
Ho. 2 1. - 8 210 5 ~l4 )380
Clonidine (xx) 1 +27-11 45/150 -12 60 5 +27-19 39/>320 -16/+45 90/120 (x) = 50#'s vaarde (xx) = 2-^,6-dichloorfenyl)-aminQ7-imidazoline-(2).
Taftel B
Verft. dosis Hart-frequentievisseling /iM/kg - 1 —--- oraal rat hond % (ft/min) duur (min) # (ft/min) duur (min)
Ho. 1 1 -10 200 -40 * 365 .
5 -16 - >3β0 -50 >400
Ho. 2 1 -13 210 5 -15 >380
Clonidine 1 -13 l60 -45 250 5 -4l )360 -66 ) 400 ft/min = slagen/minuut 7908853 «* * -5-
Tabel C
verb, dosis diuretische activiteit /uM/kg _____ oraa^ ( % toename urine-volume __ί___· 5 ffo.l 1 7¼ 5 . 184 ffo. 2 1 155 5 235
Clonidine 1 220 10 5 2
Tabel D
Verb. Verlaging van de spontane bewegelijkheid : (ED^o pM/kg oraal) j_muis rat 15 ffo. 1 80 10 ffo. 2 20 66
Clonidine 0.095 0,26 " De volgende voorbeelden lichten de uitvinding nader toe.
De smeltpunten zijn niet correct. De identiteit en de zuiverheid 20 van de verbindingen werd daarom via een elementairanalyse, infrarood, MR-en UV-spectra gemeten.
Voorbeeld I : 2-/%-(2,6-dichloorfenyl') -ff- (2-tetrahydropyranyl) amino7 imidazoline- (2)_ 25 Aan een oplossing van 2,½ g (10,2 mmol) 2-(2,6-dichloor-
O
fenylimino)-imidazoline in 60 car watervrije metbyleenchloride werd onder roeren bij kamertemperatuur 0,29 g (12,2^- mmol) ffaH langzaam toegevoegd, ffa deze toevoeging werd de oplossing nog 60 minuten geroerd, daarna op -^0°C gekoeld en een oplossing van 7908855 3 -6- .1,6 g (13,26 mmol) 2-chloor-tetrah.ydropyran in 2 cm watervrij methy leenchlori de druppelsgewijze toegevoegd. Ha deze toevoeing werd het koelbad verwijderd tot de kamertemperatuur was bereikt. Ha filtreren werd de oplossing gewassen met een verdunde oplos-, 5 sing van ammonia, daarna met natriumsulfaat gedroogd en onder verminderde druk drooggedampt. Smpt. 122-3°C (uit hexaan).
----- Op een overeenkomstige wijze werden bereid: 2-/H-( 2,6-dichloorf enyl) -H- (2-tetr ahydr ofur anyl) amino7 -imi-dazoline-(2), smpt. = 7l-2°C (u>itdiisopropylether).
10 2-^-(3-chloor-4-methylf enyl )-H-( 2-tetrahydrcpyranyl )amino7- imidazoline-(2), smpt. =- 13.5-137°C (uit hexaan).
2- ZÜ- (2-methy 1-5 -f luorf enyl) -H-( 2-tetrahydropyranyl) aminq7 -imidazoline-(2)smpt. - 125~127°C (uit hexaan).
2-/)7-(2,6-diëthy If enyl)-H-( 2-tetrahydropyranyl) amino7 -imida-15 zoline-(2), smpt. = 135~1^0°C (uit hexaan).
7908855
Claims (3)
- 5 Toor stellen., 2.
- 2-/ET-(2,6-dichloorfenyl)-!!-( tetrahydropyranyl )amino/-imidazoline-(2) en zijn farmaceutisch geschikte zouten. _ 3. 2-/ïT-( 2,6-di chloorfenyl) -W- (2-tetrahydrofuranyl) amino/- imidazoline-(2) en zijn farmaceutisch geschikte zouten. 10 if·. 2-/N-(2-chloor-k-metbylfeüyl)-I!r-(2-tetrabydropyranyl)amino/- imidazoline-(2) en zijn, farmaceutisch geschikte zouten. , 5. 2-/ST- ( 2-me thyl-5-f luorfenyl) -W- (2-tetrahydropyranyl) amino/-imidazoline-(2) en zijn farmaceutisch geschikte zouten. 6. ' 2-/F-(2, 6-di ëthylfenyl)-tf-(2-tetrahydropyranyl )-amino/-15 imidazoline-(2) en zijn farmaceutisch geschikte zouten.7. Werkwijze Toor het bereiden Tan de Terbindingen met de * formule 1 met. het. kenmerk, dat een 2-rfenylimi noimidazolidine met de formule 2 of een natriumzout daarran wordt omgezet met een Terbinding met de formule 3 of if·, waarin n de. bovenweer-20 gegeTen betekenis bezit en X een halogeenatoam (chloor of brocm), een alkoxygroep of een acyloxygroep Toorstelt, en wel bij een ^ temperatuur tussen -50°C en de kamertemperatuur in polaire of niet polaire organische oplosmiddelen, indien X een halogeenatoam is, danwel in dimethylformamide of acetonitrile bij het 25 kookpunt Tan het oplosmiddels indien X een alkoxy-, of acyloxygroep is, of indien een Terbinding met de formule if· wordt gebruikt.8. Geneesmiddelpreparaten met bloeddrukverlagende, bradycardie en diuretische activiteiten, met het kenmerk, dat zij als actieve 30 stoffen een of meer Tan de Terbihdingen volgens de conclusies 1-6 bevatten en wel in de vorm van de vrije basen of de farmaceutisch geschikte zouten daarvan. 7908853 • j * - i 4 a, Τ /-K Η-1 (θ)---ζ_ Ε ι: ^ 2 Η <0>--η-- \ Λ ]jf Η \
- 3 X 4 .5 CH (0Ηλ) ο CH Ο , \ ν 2 η / \ I (0Η2^ 0 w w ο Istituto Ijuso Farmaco d'Italia S.p.A. 7908853
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT30738/78A IT1101727B (it) | 1978-12-12 | 1978-12-12 | Nuove 2-fenilammino-imidazoline-(2) sostituite, dotate di particolari proprieta' terapeutiche, loro processo di sintesi e composizioni farmaceutiche |
IT3073878 | 1978-12-12 | ||
IT27202/79A IT1127215B (it) | 1979-11-12 | 1979-11-12 | Nuove 2-fenilammino-imidazoline-(2)sostitutite,dotate di particolari proprieta' terapeutiche,loro processo di sintesi e composizioni farmaceutiche |
IT2720279 | 1979-12-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
NL7908853A true NL7908853A (nl) | 1980-06-16 |
NL183139B NL183139B (nl) | 1988-03-01 |
NL183139C NL183139C (nl) | 1988-08-01 |
Family
ID=26328719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NLAANVRAGE7908853,A NL183139C (nl) | 1978-12-12 | 1979-12-07 | Gesubstitueerde 2-fenylamino-imidazolinen, werkwijze voor het bereiden daarvan en geneesmiddelpreparaten. |
Country Status (13)
Country | Link |
---|---|
US (1) | US4262006A (nl) |
CA (1) | CA1137090A (nl) |
CH (1) | CH645358A5 (nl) |
DE (1) | DE2949971C2 (nl) |
DK (1) | DK159317C (nl) |
ES (1) | ES8102565A1 (nl) |
FI (1) | FI65428C (nl) |
FR (1) | FR2444036A1 (nl) |
GB (1) | GB2041355B (nl) |
NL (1) | NL183139C (nl) |
NO (1) | NO152171C (nl) |
PT (1) | PT70584A (nl) |
SE (1) | SE430503B (nl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4398028A (en) * | 1977-01-14 | 1983-08-09 | Sandoz Ltd. | Bicyclic heterocyclic amino derivatives |
KR101881115B1 (ko) * | 2015-06-25 | 2018-08-20 | 가천대학교 산학협력단 | 신규 2-치환된 테트라하이드로피란 또는 2-치환된 테트라하이드로퓨란 유도체 화합물, 이의 제조방법 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3850926A (en) * | 1971-01-21 | 1974-11-26 | Boehringer Sohn Ingelheim | 2-(n-substituted-phenylamino)-imidazolines-(2) |
DD95843A5 (nl) * | 1971-01-21 | 1973-02-20 |
-
1979
- 1979-11-28 FI FI793727A patent/FI65428C/fi not_active IP Right Cessation
- 1979-11-29 CH CH1061279A patent/CH645358A5/it not_active IP Right Cessation
- 1979-11-29 CA CA000340891A patent/CA1137090A/en not_active Expired
- 1979-12-03 DK DK512479A patent/DK159317C/da not_active IP Right Cessation
- 1979-12-04 GB GB7941802A patent/GB2041355B/en not_active Expired
- 1979-12-06 US US06/100,833 patent/US4262006A/en not_active Expired - Lifetime
- 1979-12-07 NL NLAANVRAGE7908853,A patent/NL183139C/nl not_active IP Right Cessation
- 1979-12-10 SE SE7910157A patent/SE430503B/sv not_active IP Right Cessation
- 1979-12-11 NO NO794047A patent/NO152171C/no unknown
- 1979-12-11 ES ES487167A patent/ES8102565A1/es not_active Expired
- 1979-12-11 FR FR7930361A patent/FR2444036A1/fr active Granted
- 1979-12-12 PT PT70584A patent/PT70584A/pt unknown
- 1979-12-12 DE DE2949971A patent/DE2949971C2/de not_active Expired
Also Published As
Publication number | Publication date |
---|---|
NO152171C (no) | 1985-08-14 |
NL183139B (nl) | 1988-03-01 |
CH645358A5 (it) | 1984-09-28 |
DK159317B (da) | 1990-10-01 |
NO152171B (no) | 1985-05-06 |
DK512479A (da) | 1980-06-13 |
DE2949971A1 (de) | 1980-07-03 |
PT70584A (en) | 1980-01-01 |
GB2041355B (en) | 1983-02-16 |
FI65428C (fi) | 1984-05-10 |
DK159317C (da) | 1991-02-25 |
ES487167A0 (es) | 1980-12-16 |
SE430503B (sv) | 1983-11-21 |
ES8102565A1 (es) | 1980-12-16 |
SE7910157L (sv) | 1980-06-13 |
FI65428B (fi) | 1984-01-31 |
FR2444036A1 (fr) | 1980-07-11 |
GB2041355A (en) | 1980-09-10 |
NL183139C (nl) | 1988-08-01 |
DE2949971C2 (de) | 1983-11-24 |
FI793727A (fi) | 1980-06-13 |
CA1137090A (en) | 1982-12-07 |
US4262006A (en) | 1981-04-14 |
FR2444036B1 (nl) | 1985-03-15 |
NO794047L (no) | 1980-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69304243T2 (de) | Chinolin-Verbindungen als Angiotensin-II-Antagoniste | |
DE60125980T2 (de) | P38kinase-inhibitoren vom piperidin/piperazin-typ | |
EP1399423B1 (de) | Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe | |
CH649527A5 (de) | 1,2-diaminocyclobuten-3,4-dione, verfahren zu deren herstellung und pharmazeutische mittel, die diese verbindungen enthalten. | |
EP0047923B1 (de) | Isochinolinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
EP0053767B1 (de) | Tricyclische Cytosinderivate zur Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung | |
EP0008652B1 (de) | Neue Zwischenprodukte und deren Verwendung zur Herstellung von neuen Oxadiazolopyrimidinderivaten | |
DE2308883C3 (de) | 2-Phenylamino-thienylmethyl-imidazoline-(2), Verfahren zur Herstellung derselben und diese enthaltene Arzneimittel | |
DE2362754A1 (de) | Cyclopropylmethylamine, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel | |
EP0526395A1 (de) | Arylalkylaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
JPH02235868A (ja) | グアニジン誘導体 | |
NL7908853A (nl) | Gesubstitueerde 2 fenylamino-imidazolinen. | |
PT78491B (en) | Process for the preparation of new 5-acyl-2-(1h)-pyridinones useful as cardiotonic agents | |
NO300839B1 (no) | Nye 2-cyano-3-hydroksy-propenamider og farmasöytiske preparater inneholdende slike | |
EP0430693B1 (en) | Pyrimidinedione derivative compounds, method for preparing same, and antiarrhythmic agents containing same | |
DE69629931T2 (de) | 1-(hetero)aryl-4-(kondensiertes thiazol-2-ylalkyl)-piperazin derivate, deren herstellung und deren verwendung in der behandlung von 5-ht1a-rezeptor vermittelten krankheiten | |
DE3875820T2 (de) | Aromatische heterozyklische karbonsaeureamidabkoemmlinge, verfahren zur herstellung und arzneimittel, die diese enthalten. | |
US4503051A (en) | Substituted 3-cyclobutene-1,2-diones, pharmaceutical compositions thereof and methods of use | |
DE2831671A1 (de) | Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben | |
DE2946212A1 (de) | Azepino eckige klammer auf 1,2,3-1m eckige klammer zu- beta -carbolin-verbindungen, verfahren zu deren herstellung und arzneimittel, welche die verbindungen enthalten | |
DE3134945A1 (de) | Substituierte 2-amino-3,4-dihydropyridinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimittel | |
NO151412B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater | |
DE69509510T2 (de) | 2-(aminoalkoxy) phenylalkylamine mit entzündungskennenden eigenschaften | |
KR0130758B1 (ko) | 피리딘카복실산 아미드 유도체 및 이를 포함하는 약제학적 조성물 | |
EP0037471B1 (de) | 1-Aroyl-2-phenylamino-2-imidazoline, ihre Herstellung und diese enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BA | A request for search or an international-type search has been filed | ||
BB | A search report has been drawn up | ||
BC | A request for examination has been filed | ||
A85 | Still pending on 85-01-01 | ||
V1 | Lapsed because of non-payment of the annual fee |